RxDoctor Payments Data

Alfred Kohan, MD

Urology · Plainview, NYNPI 1831152768

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (47.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 46 manufacturers reported payments, led by Ferring Pharmaceuticals Inc. at 59.7% of the total. Reporting peaked in 2019 at $31,846 and has fallen 93.2% since, to $2,155 in 2025. Among urology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$52,089in general payments, 2019–2025

Across 509 payments — averaging $102.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ferring Pharmaceuticals Inc.$31K
  • AbbVie$9K
  • Neotract Inc.$2K
  • Medtronic$1K
  • Johnson & Johnson$1K
  • Astellas Pharma US Inc$981
  • plus $7K from 40 others
$103,936in research payments, 2019–2025

Across 23 payments — averaging $4518.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$84K
  • Ipsen Innovation$20K

What the payments were for

  • Consulting fees$1,3833%
  • Speaking & faculty fees$24,96948%
  • Travel & lodging$13,08125%
  • Food & beverage$12,10223%
  • Education$5551%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,089 in reported general payments places this provider in the 90th percentile of 952 urology providers in New York.

See all urology providers in New York →

Medicare billing

Part B allowed, 2024
$832,996
Medicare patients
945
Services billed
28,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide13$171,105
GemtesaVibegron172$168,004
MyrbetriqMirabegron116$99,484
Abiraterone Acetate13$70,769
OrgovyxRelugolix16$48,611
XyostedTestosterone Enanthate47$28,396
Tamsulosin Hcl934$17,662
Mirabegron ErMirabegron11$10,251
Silodosin96$9,117
Trospium Chloride ErTrospium Chloride49$9,013
Methenamine Hippurate76$8,130
Potassium Citrate ErPotassium Citrate50$6,844
Solifenacin Succinate97$6,439
Cephalexin127$6,024
Finasteride362$5,374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$841$216,616188 claims
BayerNubeqa$664$171,10513 claims
Astellas Pharma US IncMyrbetriq$981$99,484116 claims
Antares Pharma, Inc.Xyosted$230$28,39647 claims
PfizerPremarin$243$4,66711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 952 urology providers in New York.

Other urology in Plainview

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →